Mesoblast eyes AMD indication with new stem cell therapy trial
This article was originally published in Clinica
Executive Summary
Mesoblast will be evaluating its stem cell therapy in eye disease for the first time, after being cleared to start a Phase II trial of its off-the-shelf technology in age-related macular degeneration (AMD). The trial will enrol 18 patients in Singapore with neovascular, or wet, AMD, which is thought to account for around 90% of blindness in the elderly.